In a clinical trial (ClinicalTrials.gov Identifier: NCT01989208), the authors investigated the effects of H2S donor SG1002 on heart failure, and they found that administration of SG1002 increased H2S levels and circulating NO bioavailability, but attenuated BNP levels in heart failure patients (Polhemus et al., 2015). The gene discussed is NPPB; the disease is heart failure.